Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
CONCLUSION: Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy.PMID:38650099 | DOI:10.4093/dmj.2023.0259
Source: Diabetes and Metabolism Journal - Category: Endocrinology Authors: Ji-Yeon Park Joonyub Lee Yoon-Hee Choi Kyung Wan Min Kyung Ah Han Kyu Jeung Ahn Soo Lim Young-Hyun Kim Chul Woo Ahn Kyung Mook Choi Kun-Ho Yoon Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators Source Type: research
More News: Actos | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Insulin | Metformin | Study